Phase I Study of HMPL-523+Azacitidine in Elderly Patients With Acute Myeloid Leukemia
Status:
Terminated
Trial end date:
2019-09-09
Target enrollment:
Participant gender:
Summary
This is a Phase I, open-label, non-randomized, multicenter study to evaluate the safety,
pharmacokinetics and preliminary efficacy of HMPL-523 in combination with Azacitidine in
previously untreated elderly patients with AML who are not eligible for standard induction
therapy.